We contribute to significant advances in medical treatments through our revolutionary 3D tissue-engineering technology.
Because our society faces an aging population and increasing prevalence of chronic diseases, regenerative medicine will play a growing and important role in patient care, particularly where satisfaction is low with medical treatments using traditional drugs, devices, and surgery.

In addition to cell quality, the performance of cellular products relies on their composition. The conventional approach of injecting cell suspension has proved unsuitable for regenerating solid tissue because it does not introduce sufficient cell numbers while scaffolding, such as with animal-derived collagen, raises safety concerns related to allergies and viral vectors.

With our proprietary tissue-engineering technologies, cellular aggregates are assembled into three-dimensional macrostructures without the need for scaffolding materials. The subsequent self-organization/maturation process in our customized bioreactor generates functional tissues/organs.

To promote our platform technologies, we successfully developed the BIO 3D PRINTER, Regenova®. Regenova® is a state-of-the-art robotic system that enables fully automated fabrication of three-dimensional artificial tissues/organs from living cells.